CRINETICS PHARMACEUTIC

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

28 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

14 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 ноя 2022 15:30:43 Источник Nasdaq GlobeNewswire

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

13 окт 2022 07:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 окт 2022 15:57:25 Источник Nasdaq GlobeNewswire

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

06 окт 2022 07:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

03 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

08 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

02 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 авг 2022 15:44:12 Источник Nasdaq GlobeNewswire

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

04 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 16:09:22 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 июн 2022 15:30:47 Источник Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 май 2022 06:00:00 Источник Nasdaq GlobeNewswire